Pfizer And Moderna’s Cold War On COVID Gets Competitive
Biotech Talks Up Refrigeration Advantage
Ahead of anticipated emergency use approvals, Pfizer and Moderna are promoting the benefits of their rival mRNA vaccines.
You may also be interested in...
Results of a forthcoming APhA survey show more than one-third of pharmacies are fully prepared to administer the vaccines once they are available, with more still preparing.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
Topline results have produced a lower efficacy rate than seen in the Pfizer and Moderna trials, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.